Form 4: Director David E.I. Pyott Acquires TARSUS PHARMACEUTICALS Stock

Director David E.I. Pyott acquired 1,383 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units.

Summary

• Director David E.I. Pyott acquired 1,383 shares of Tarsus Pharmaceuticals, Inc. common stock on April 24, 2026.
• The acquisition occurred through the settlement of vested Restricted Stock Units (RSUs).
• Following this transaction, Mr. Pyott beneficially owns 7,991 shares of common stock, held indirectly through the David E.I. Pyott Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider buying can be positive, this transaction represents the settlement of vested equity awards rather than an open market purchase, making its signal less strong.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• Vesting of RSUs indicates that performance or service conditions have been met.

Future Outlook

No specific forward-looking statements or guidance are present in this Form 4 filing, which solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Tarsus Pharmaceuticals, are standard disclosures for insider transactions. Such filings are closely watched by investors for insights into management's perception of the company's value and future performance.

Stakeholder Impact

• Shareholders: The acquisition by a director may be interpreted positively, suggesting insider confidence in the company's stock value.

Key Dates

Keywords

Form 4, SEC Filing, Tarsus Pharmaceuticals, TARS, David E.I. Pyott, Director, Restricted Stock Units, RSUs, Common Stock, Beneficial Ownership